Abstract
The distribution of abacavir into the cerebrospinal fluid (CSF) was assessed by use of a population pharmacokinetic analysis. Plasma and CSF abacavir concentrations in 54 subjects were determined. The abacavir CSF/plasma ratio averaged 36% and increased throughout the dose interval. Abacavir penetrates into the CSF in adequate concentrations to inhibit local human immunodeficiency virus replication.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / cerebrospinal fluid*
-
Anti-HIV Agents / pharmacokinetics*
-
Dideoxynucleosides / administration & dosage
-
Dideoxynucleosides / cerebrospinal fluid*
-
Dideoxynucleosides / pharmacokinetics*
-
Drug Therapy, Combination
-
HIV Infections / drug therapy
-
HIV Infections / virology
-
HIV-1 / drug effects
-
Humans
-
Male
-
Models, Biological
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Reverse Transcriptase Inhibitors / cerebrospinal fluid
-
Reverse Transcriptase Inhibitors / pharmacokinetics*
-
Software
Substances
-
Anti-HIV Agents
-
Dideoxynucleosides
-
Reverse Transcriptase Inhibitors
-
abacavir